US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
pharma · Chronic Lymphocytic Leukemia (CLL) · Chronic Lymphocytic Leukemia · APVO
Aptevo Therapeutics
Aptevo Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Seattle, USA HQ
2016 Founded
54 Employees
Public company Type
APVO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Seattle, USA
- Founded
- 2016
- Employees
- 54
- Programs
- 9
- Drugs
- 4
- Patents
- 13
Aptevo Therapeutics pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Aptevo Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Aptevo Therapeutics in public FDA and regional records.
-
Development asset linked to Aptevo Therapeutics in public FDA and regional records.
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent